Author

J.-P. Sommadossi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Assay:structural biology· 1

Frequent Co-Authors

A. Moussa· 2 shared B. Canard· 2 shared A. Shannon· 1 shared B. Sama· 1 shared B. Selisko· 1 shared C. Eydoux· 1 shared C. Falcou· 1 shared E. Decroly· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

A. Moussa

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BiochemistrybioRxivMar 23, 2021

Protein-primed RNA synthesis in SARS-CoVs and structural basis for inhibition by AT-527

A. Shannon, V. Fattorini, B. Sama…·B. Canard

This paper identifies a protein-priming mechanism for SARS-CoV RNA synthesis and shows that AT-527 inhibits this process by targeting both NiRAN and RdRp domains.

DOI 10.1038/s41467-022-28113-1

humanstructural biology

𝕏 PostBluesky

Pharmacology & ToxicologybioRxivPreprintAug 11, 2020

AT-527 is a potent in vitro replication inhibitor of SARS-CoV-2, the virus responsible for the COVID-19 pandemic

S. S. Good, J. Westover, K. H. Jung…·J.-P. Sommadossi

The paper reports that AT-511, a form of AT-527, is a potent in vitro inhibitor of SARS-CoV-2 replication with low cytotoxicity.

DOI 10.1101/2020.08.11.242834

humanexperimental assay

𝕏 PostBluesky